Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07306338 | Patient Interest in an Integrative Oncology Program at USC Norris Cancer Center: A Single-Institution Needs Assessment | recruiting | — | 10 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07408375 | Effect of a Driving Pressure Adjustment Procedure for High-Frequency Jet Ventilation in Patients Undergoing Tumor Thermal Ablation in Interventional Radiology(Pulmojet 3) | recruiting | N/A | 560 | Nantes University HospitalOTHER | 1 |
| Mar 27, 2026 |
| clinicaltrials |
| NCT03667170 | KN035 for dMMR/MSI-H Advanced Solid Tumors | recruiting | Phase 2 | 200 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04891198 | ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors | recruiting | Phase 2 | 126 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07262164 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Shanghai Virogin Biotech Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05727839 | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | completed | Phase 1 | 19 | Immorna Biotherapeutics, Inc.INDUSTRY | 2 | Mar 24, 2026 | clinicaltrials |
| NCT06781125 | One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 72 | Immorna Biotherapeutics, Inc.INDUSTRY | 0 | Mar 24, 2026 | clinicaltrials |
| NCT05988892 | A Study of Physical Activity in Cancer Survivors | completed | N/A | 100 | Mayo ClinicOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07222969 | A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 146 | Vibrant Sciences LimitedINDUSTRY | 2 | Mar 23, 2026 | clinicaltrials |
| NCT07482319 | A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors | not yet recruiting | Phase 1 | 15 | Beijing Geekgene Technology Co., LTDINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07487597 | Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors | recruiting | Early Phase 1 | 24 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | active not recruiting | Phase 1 / Phase 2 | 253 | Taiho Oncology, Inc.INDUSTRY | 8 | Mar 20, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04419532 | A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 40 | Daiichi SankyoINDUSTRY | 3 | Mar 20, 2026 | clinicaltrials |
| NCT07032077 | A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors | recruiting | Phase 2 | 100 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07229638 | A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT00900471 | Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors | recruiting | — | 20,000 | Wake Forest University Health SciencesOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02789228 | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors(REST) | active not recruiting | Phase 1 | 28 | Children's National Research InstituteOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03347318 | Target Therapies Resistance Molecular Profiling in Patients With Neoplastic Disease(PROFILING) | active not recruiting | — | 2,500 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05306509 | Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology(NiCE) | recruiting | N/A | 120 | Children's Hospital of Fudan UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT06357975 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) | active not recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07477886 | Ambient Sensing Room to Detect Early Signs of Adverse Events in Hospitalized Patients With Cancer | recruiting | — | 134 | Mayo ClinicOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT00571389 | A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells. | recruiting | — | 1,500 | BioCytics, Inc.INDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Mayo ClinicOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04143711 | Study of DF1001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 270 | Dragonfly TherapeuticsINDUSTRY | 6 | Mar 18, 2026 | clinicaltrials |
| NCT04158336 | A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors | completed | Phase 1 | 274 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04423029 | A Study of DF6002 Alone and in Combination With Nivolumab | completed | Phase 1 | 170 | Dragonfly TherapeuticsINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT04443088 | An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors(KEYNOTE-E12) | recruiting | Phase 1 | 78 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05101070 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors(aCCeleR8-001) | recruiting | Phase 1 / Phase 2 | 282 | ShionogiINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT05689853 | Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 87 | AkesoINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06108479 | Study of DF6215 in Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Dragonfly TherapeuticsINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT06422455 | Access to Genetic Testing in Underserved Patients With Cancer | recruiting | N/A | 800 | University of Southern CaliforniaOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation(ALAFOSS-01) | terminated | Phase 1 | 17 | AstraZenecaINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT06799533 | A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 | 11 | PfizerINDUSTRY | 5 | Mar 18, 2026 | clinicaltrials |
| NCT06804824 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 220 | Vividion Therapeutics, Inc.INDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT07479667 | An Antibody-armored Dendritic Cell in Patients With Solid Tumors(dendritic cell) | recruiting | Phase 1 | 8 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | active not recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05023655 | Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | terminated | Phase 2 | 20 | Prisma Health-UpstateOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06056024 | A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus | completed | Phase 1 | 47 | Boehringer IngelheimINDUSTRY | 4 | Mar 17, 2026 | clinicaltrials |
| NCT01248429 | Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases(TKI-CPK) | completed | — | 154 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT01415258 | Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre(VULNERABILITE) | completed | — | 209 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03725436 | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05112614 | Role of Gut Microbiome in Cancer Therapy | recruiting | — | 3,000 | Mayo ClinicOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06540066 | A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 35 | BeiGeneINDUSTRY | 3 | Mar 16, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 27, 2026source: clinicaltrials